HD-OPM Archive
Topics › LDL, ApoB & lipid panel

CSL112 ApoA-I infusion failed in phase 3 AEGIS-II, supporting HDL as marker not cause

Louis Nervegna · Feb 13, 2024 · ♥ 8 reactions · 5 comments · original Facebook post
LDL, ApoB & lipid panelInsulin resistance & diabetesHeart attack, stroke & procedures
AI summary & key facts

Louis argues the failure of AEGIS-II, in which patients received native ApoA-I (CSL112), shows ApoA-I is not directly causal in heart disease. Every large pharmaceutical trial raising HDL or ApoA-I has failed to prevent heart attacks and strokes. HDL and ApoA-I remain good risk markers, probably standing in for insulin resistance, so raising them by means other than improving insulin sensitivity may not lower risk.

Another very large randomized controlled trial testing an intervention to raise HDL (in this case ApoA1) has failed.

They literally gave patients native ApoA1 isolated from human plasma (CSL112) and it still failed in this large phase 3 trial. This proves definitively that ApoA1 by itself is not directly causal in heart disease.

So far, every single large RCT that has ever tested pharmaceutical interventions to raise HDL and/or ApoA1 has failed to prevent heart attacks and strokes.

This does NOT mean that HDL or ApoA1 are bad markers for risk— they are good markers— but it does provide clear evidence that they are not causal by themselves.

If not directly causal by themselves, then the really interesting question becomes:
What are they actually markers for? Most researchers suspect insulin resistance.

An important corollary here is the following: If you are trying to raise your HDL or ApoA1 by any method besides improving insulin sensitivity, then there is a good chance that this will not actually lower your risk— because HDL by itself does not appear to be directly causal. However, insulin resistance is causal.

#hdlHD #apoa1HD #insulinresistanceHD #csl112HD

Global Newsroom | CSLCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...newsroom.csl.com

Research cited

← newer: Short video quiz: why men have fewer heart attacks the day aolder: In JUPITER, rosuvastatin brought diabetes diagnosis forward →